Are Cancer Patients Getting Treated in Time?

Cancer is the second most common cause of death in the UK. Some 376,000 new cases are diagnosed each year and 167,000 people die from the disease — one in two people born after 1960 will receive a cancer diagnosis in their lifetime. The NHS Long-Term Plan committed to diagnosing 75% of cancers at stage 1 or 2 by 2028, yet the current figure sits at around 54%, well behind Denmark and Sweden where 60–65% are caught early. Late-stage diagnosis is the primary driver of the UK's survival gap: five-year bowel cancer survival is 57% here against 67% in Australia; ovarian cancer survival is 35% compared with 45%. Deprivation is the strongest predictor of late presentation — patients in the least deprived quintile are 30% more likely to be diagnosed at stage 1.

The 62-day urgent referral-to-treatment standard has not been met since 2015. By 2023 the compliance rate had fallen to 67.4% against an 85% target, while 16,200 patients were waiting more than 104 days for treatment to begin. COVID-19 inflicted catastrophic disruption: an estimated 350,000 fewer cancers were diagnosed in 2020, and the resulting diagnostic backlog has never fully cleared. GP referral rates vary threefold across practices, creating a postcode lottery at the point of entry, and one-year bowel cancer survival ranges from 89% to 93% across NHS regions — a gap that reflects systemic variation in access rather than biology.

Workforce and equipment shortages sit behind the numbers. England faces a 20% shortfall in clinical oncologists and a 30% shortfall in histopathologists. CT scanner density is among the lowest in western Europe at 7.1 per million population, against an EU average of 25.8. Endoscopy capacity falls short of demand — 2.8 million procedures are needed annually but only 2.3 million are delivered. Despite these constraints, five-year survival has risen from 50% to 56% since 2010, breast cancer survival now exceeds 85%, and the Targeted Lung Health Check programme has detected cancers at early stage in 75% of cases. Immunotherapy and CAR-T cell therapy are transforming outcomes for certain blood cancers, though equitable access to these treatments remains uneven across the country.

The burden falls unevenly. Lung cancer — the biggest killer — accounts for 21% of cancer deaths but receives less research funding per death than breast or prostate cancer. Patients in the most deprived quintile are 60% more likely to be diagnosed with lung cancer and 15% less likely to receive curative surgery. Black women in England wait on average 4.5 days longer from urgent referral to first diagnostic test than white women, and South Asian patients present with later-stage colorectal cancer at significantly higher rates. Geographically, the South West and East of England consistently meet waiting-time targets while trusts in the North West and Midlands fall furthest behind. Diagnostic capacity is the binding constraint: community diagnostic centres were meant to number 160 by 2025, but fewer than 100 are fully operational. Rural patients travel further for radiotherapy — 40% of those in the most remote areas face round trips exceeding 90 minutes — and distance from a radiotherapy centre correlates with lower uptake of treatment.

Cancer statistics in England are fragmented across multiple bodies, making a single coherent picture difficult to assemble. NHS England publishes waiting-time data monthly, but survival statistics from the Office for National Statistics lag by two to three years because five-year follow-up is required. Stage-at-diagnosis data — arguably the most important metric — is published by the National Cancer Registration and Analysis Service with a two-year delay and covers only 70% of cases with a confirmed stage. The 62-day waiting-time clock starts at urgent GP referral, meaning cancers detected through screening or emergency admission follow different pathways that are not captured in the headline figure. COVID-era data is particularly unreliable: reduced GP consultations in 2020–21 suppressed referral numbers, creating an artificial improvement in compliance rates that masked a growing undiagnosed backlog. International comparisons are complicated by differing cancer registration practices — the UK's completeness is among the best in Europe, which may paradoxically make its survival figures look worse relative to countries with less thorough registration.